<DOC>
	<DOCNO>NCT01974271</DOCNO>
	<brief_summary>This prospective , multicenter , observational study evaluate impact comorbidities hemoglobin stability chronic kidney disease patient dialysis treat Mircera ( methoxy polyethylene glycol-epoetin beta ) . Eligible patient follow 6 month treatment .</brief_summary>
	<brief_title>An Observational Study Hemoglobin Stability Chronic Kidney Disease Patients Dialysis Treated With Mircera ( Methoxy Polyethylene Glycol-epoetin Beta )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic kidney disease patient hemodialysis hemodiafiltration least 3 month Previously treat erythropoietin stimulating agent ( ESA ) Patient investigator decide initiate treatment Mircera medical reason Last hemoglobin level initiation Mircera within range 1012 g/dL Current participation clinical trial renal anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>